Indian Pharmaceutical Stocks Continue Monday August 3 Morning Selloff Following President Trump's Truth Social Post Confirming the Phased Generic-Drug Tariff Schedule (Zero Duty for Two Years Starting August 1 2026, Then 100% Starting August 1 2028, Then 200% Starting August 1 2029); Nifty Pharma Slumps Nearly 2% Making It the Worst-Performing Sectoral Index on the National Stock Exchange in Early Trade With Gland Pharma Leading Losses Down 4.54%, Cipla Down 1.95%, Sun Pharma Down 1.29%, and Dr Reddy's Down Similarly Given India Supplies Approximately 50% of US Generic Prescriptions by Volume
Indian pharmaceutical stocks continued the Monday August 3, 2026 morning selloff following President Trump's Truth Social post confirming the phased generic-drug tariff schedule. The Nifty Pharma index slumped nearly 2% in early trade, making it the worst-performing sectoral index on the National Stock Exchange. Individual stock movements: Gland Pharma led losses down 4.54% to Rs 2,362.5; Cipla, Sun Pharma, and Dr Reddy's Laboratories were among the top early losers at down 1.29-1.95%; Ajanta Pharma, Alkem Laboratories, Mankind Pharma, and Divi's Laboratories all traded 1.3-3% lower. Sensex fell over 400 points; Nifty slipped below 24,150. The tariff schedule: zero duty for two years starting August 1, 2026, then 100% starting August 1, 2028, then 200% starting August 1, 2029. Tariffs on patented and branded medicines (separately governed by Section 232) remain unchanged. India supplies approximately 50% of US generic prescriptions by volume (over 90% of US prescriptions overall are generics). US production costs would be 25-30% higher than in India, making the two-year transition challenging for large-scale onshoring. Analyst commentary suggests creating a viable US generic manufacturing ecosystem would take at least five years.